145 related articles for article (PubMed ID: 18592865)
1. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy].
Mrochem-Kwarciak J; Mrochen-Domin I; Wojcieszek A; Deja R; Chmura A; Masłyk B; Nowara E; Kaleta B; Kołosza Z; Bartnik W
Ginekol Pol; 2011 Dec; 82(12):911-7. PubMed ID: 22384627
[TBL] [Abstract][Full Text] [Related]
4. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
5. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
6. Serum protein markers for early detection of ovarian cancer.
Mor G; Visintin I; Lai Y; Zhao H; Schwartz P; Rutherford T; Yue L; Bray-Ward P; Ward DC
Proc Natl Acad Sci U S A; 2005 May; 102(21):7677-82. PubMed ID: 15890779
[TBL] [Abstract][Full Text] [Related]
7. Role of osteopontin in differential diagnosis of ovarian tumors.
Moszynski R; Szubert S; Szpurek D; Michalak S; Sajdak S
J Obstet Gynaecol Res; 2013 Nov; 39(11):1518-25. PubMed ID: 23875677
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma.
Milivojevic M; Boskovic V; Atanackovic J; Milicevic S; Razic S; Kotlica BK
Eur J Gynaecol Oncol; 2013; 34(1):83-5. PubMed ID: 23590008
[TBL] [Abstract][Full Text] [Related]
10. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours.
He G; Holcroft CA; Beauchamp MC; Yasmeen A; Ferenczy A; Kendall-Dupont J; Mes-Masson AM; Provencher D; Gotlieb WH
J Obstet Gynaecol Can; 2012 Jun; 34(6):567-574. PubMed ID: 22673173
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
Gschwantler-Kaulich D; Weingartshofer S; Rappaport-Fürhauser C; Zeillinger R; Pils D; Muhr D; Braicu EI; Kastner MT; Tan YY; Semmler L; Sehouli J; Singer CF
PLoS One; 2017; 12(12):e0189641. PubMed ID: 29244844
[TBL] [Abstract][Full Text] [Related]
12. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
13. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
Pils D; Tong D; Hager G; Obermayr E; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Van Gorp T; Mahner S; Concin N; Speiser P; Zeillinger R
BMC Cancer; 2013 Apr; 13():178. PubMed ID: 23551967
[TBL] [Abstract][Full Text] [Related]
14. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
16. Alternatives to risk-reducing surgery for ovarian cancer.
Gadducci A; Sergiampietri C; Tana R
Ann Oncol; 2013 Nov; 24 Suppl 8():viii47-viii53. PubMed ID: 24131970
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases.
Park EK; Johnson AR; Yates DH; Thomas PS
Clin Chem Lab Med; 2011 Jan; 49(1):147-50. PubMed ID: 20961188
[TBL] [Abstract][Full Text] [Related]
19. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract][Full Text] [Related]
20. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
Gorelik E; Landsittel DP; Marrangoni AM; Modugno F; Velikokhatnaya L; Winans MT; Bigbee WL; Herberman RB; Lokshin AE
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):981-7. PubMed ID: 15824174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]